PPMO's as therapeutic modulators for myotonic dystrophy type 1

Ítems similars

• Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
  per: Holland, A, et al.
  Publicat: (2018)
• Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
  per: Klein, AF, et al.
  Publicat: (2019)
• Application of antisense conjugates for the treatment of myotonic dystrophy type 1
  per: Stoodley, J, et al.
  Publicat: (2023)
• Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
  per: Liubov V. Gushchina, et al.
  Publicat: (2022-12-01)
• Cardiac manifestations in myotonic dystrophy type 1
  per: A. G. Klementieva, et al.
  Publicat: (2024-09-01)